A. Suehiro, M. Marumo, H. Yoshimoto
Feb 1, 2000
Citations
0
Influential Citations
3
Citations
Quality indicators
Journal
Current Therapeutic Research-clinical and Experimental
Abstract
Abstract Although sarpogrelate hydrochloride is known to be a selective S2-serotonergic receptor antagonist for platelets, the direct effect of sarpogrelate on serotonin-induced platelet activation has not been evaluated previously. The purpose of this study was to examine the in vitro effect of sarpogrelate on small-aggregate formation induced by serotonin by means of a particle-counting method using light scattering. Both 1 μM and 10 μM of serotonin-induced small-aggregate formations in platelet-rich plasma obtained from healthy volunteers were dose-dependently inhibited by the addition of 0.1 to 10 μM of sarpogrelate. The concentration of sarpogrelate causing 50% inhibition of the control response was calculated as 4.6 μM and 7.4 μM in 1 μM and 10 μM of serotonin-induced small-aggregate formation, respectively. Results of this study suggest that sarpogrelate inhibits serotonin-induced platelet activation and may thus be a useful antiplatelet agent.